Alison Y. Zhang

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.6K citations

Pharmacy, Oncology, Pharmacotherapy +17

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +12

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

James P Buteau, Andrew Martin, Louise Emmett et al. · The Lancet Oncology · 2022 · 266 citations

Medicine, Oncology, Pharmacotherapy +16

TheraP: a randomized phase 2 trial of ¹⁷⁷ Lu‐ <scp>PSMA</scp> ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol <scp>ANZUP</scp> 1603)

Michael S. Hofman, Louise Emmett, John Violet et al. · British Journal of Urology · 2019 · 162 citations · Full text

Medicine, Oncology, Pharmacology +17

Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer

Seher Balaban, Zeyad D. Nassar, Alison Y. Zhang et al. · Molecular Cancer Research · 2019 · 87 citations

Life Sciences, Biochemistry, Cell Biology +17